The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts).
 
Yasser Ged
No Relationships to Disclose
 
Joshua Chaim
No Relationships to Disclose
 
Andrea Knezevic
No Relationships to Disclose
 
Maria Isabel Carlo
Consulting or Advisory Role - Pfizer
 
Ashley Foster
No Relationships to Disclose
 
Darren R. Feldman
Research Funding - Novartis; Seagen
Other Relationship - UpToDate
 
Min Yuen Teo
Research Funding - Bristol-Myers Squibb
 
Nadeem Riaz
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Pfizer
 
Chung-Han Lee
Consulting or Advisory Role - Eisai; Eisai; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai
 
Sujata Patil
No Relationships to Disclose
 
Timothy An-thy Chan
Leadership - Bristol-Myers Squibb; Cancer Genetics; Illumina
Stock and Other Ownership Interests - Gritstone Bio
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Neoantigen discovery and genomic biomarkers for immunotherapy response
 
A. Ari Hakimi
No Relationships to Disclose
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Corvus Pharmaceuticals; Eisai; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche
Travel, Accommodations, Expenses - Eisai; MedImmune; Takeda